Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diamel + insulin refers to the co-administration of the multi-component dietary supplement Diamel with exogenous insulin for the management of diabetes mellitus. Diamel, developed by Catalysis S.L., is a nutraceutical formulation containing a blend of antioxidants, amino acids (such as arginine and glycine), vitamins, and minerals (including zinc) designed to reduce oxidative stress and improve metabolic parameters. When used as an adjuvant to insulin therapy, Diamel aims to enhance glycemic control, potentially reducing the required insulin dose and mitigating long-term complications associated with chronic hyperglycemia. The supplement components support insulin sensitivity and pancreatic function, while its antioxidant profile addresses the inflammatory state characteristic of diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diamel + insulin.